MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO announces the expansion of existing Spray Dry Development & Production Services in North America. The Canadian facility, located in Mississauga, ON, has expanded its cGMP Spray Drying capabilities with the addition of a GEA Mobile Minor spray drying system and dedicated 500 sq. ft. clean room.
With this expansion, Eurofins CDMO can further complement a broad range of services specializing in solubility enhancement for clinical development and small scale commercial programs. Its process capabilities include solvent or aqueous systems, highly potent compounds, API and Drug Product development and manufacturing, solid state characterization, oral solid and inhalation dosage forms.
The expansion of Spray Drying at Eurofins CDMO provides continued support of clinical development programs where formulation enabling is required for poorly soluble compounds.
The new Spray Dry system enables manufacturing of solid dispersions at multi-kilo scale in support of a wide range of finished dosage forms for early clinical through to niche commercial programs.
About Eurofins CDMO
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization that provides clients with Active Pharmaceutical Ingredients (API’s) / Drug Substance and Drug Product development for small molecules and biologicals. Its service offering encompasses Drug Substance/API Development, Solid State Research and Development, Pre-formulation, Formulation and Development, Analytical Development, GMP Manufacturing and Clinical Packaging and Logistics. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.
About Eurofins – the global leader in bio-analysis
Eurofins (Paris:ERF) is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.